Equities researchers at Ladenburg Thalmann Financial Services initiated coverage on shares of Mast Therapeutics (NASDAQ:SVRA) in a research report issued on Wednesday. The firm set a “buy” rating and a $35.00 price target on the stock. Ladenburg Thalmann Financial Services’ price objective indicates a potential upside of 135.37% from the stock’s previous close.

A number of other equities research analysts have also recently issued reports on SVRA. Zacks Investment Research cut shares of Mast Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, September 7th. JMP Securities initiated coverage on shares of Mast Therapeutics in a report on Monday, September 11th. They set an “outperform” rating and a $20.00 price target for the company. Jefferies Group initiated coverage on shares of Mast Therapeutics in a research report on Friday, September 22nd. They set a “buy” rating and a $20.00 price objective for the company. Roth Capital reaffirmed a “buy” rating and set a $40.00 price objective on shares of Mast Therapeutics in a research report on Wednesday, September 27th. Finally, Canaccord Genuity upped their price objective on shares of Mast Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, October 30th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Mast Therapeutics currently has an average rating of “Buy” and an average price target of $23.58.

Shares of Mast Therapeutics (SVRA) traded up $0.03 during trading hours on Wednesday, reaching $14.87. 97,200 shares of the company were exchanged, compared to its average volume of 98,900. The company has a market capitalization of $467.58, a PE ratio of -4.43 and a beta of 0.18. Mast Therapeutics has a 12-month low of $4.60 and a 12-month high of $17.19. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 9.15.

In other Mast Therapeutics news, Director Yuri Pikover purchased 50,000 shares of the company’s stock in a transaction that occurred on Friday, October 27th. The stock was purchased at an average price of $7.85 per share, with a total value of $392,500.00. Following the completion of the transaction, the director now directly owns 150,000 shares of the company’s stock, valued at approximately $1,177,500. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 6.93% of the company’s stock.

WARNING: This article was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/03/mast-therapeutics-svra-coverage-initiated-at-ladenburg-thalmann-financial-services.html.

Mast Therapeutics Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Analyst Recommendations for Mast Therapeutics (NASDAQ:SVRA)

Receive News & Ratings for Mast Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.